The FDA has sent a proposed peptide interim access policy to the White House for review. It could temporarily let compounding pharmacies make and sell some previously restricted peptides.
Follow the storyWhite House4 stories
01Summary
- 01The Food and Drug Administration submitted a peptide “interim access policy” to the White House for review this week.
- 02The proposal would reportedly allow compounding pharmacies to temporarily produce and sell previously restricted peptides.
- 03The filing is described in The Hill as part of an apparent peptide push linked to RFK Jr.
- 04The source text does not give details on which peptides would be covered or when any change would take effect.
02Why it matters
The move could affect how some medicines are supplied and sold in the United States. It also signals a possible regulatory shift for compounding pharmacies and patients using peptide products.
Pulse AIAsk about this story
Answers are generated by AI from the story summary; they are not investment, health or legal advice.
